Tango Therapeutics Inc Stock Price, News & Analysis

Tango Therapeutics, a clinical-stage biotechnology firm (NASDAQ: TNGX), has appointed Adam Crystal, M.D., Ph.D. as President of Research and Development. Dr. Crystal will lead preclinical research, drug discovery, and clinical development, working with existing leaders in the company. Tango is currently enrolling patients in a crucial clinical trial and plans to introduce three more programs in the next year. Dr. Crystal's expertise in precision oncology is expected to enhance the advancement of Tango's pipeline, which focuses on synthetic lethal targeting in cancer treatment.

Tango Therapeutics (NASDAQ: TNGX), a clinical-stage biotechnology company focused on precision cancer medicine, is set to participate in key investor conferences this February. The first event is the Guggenheim Healthcare Talks | 2023 Oncology Conference on February 9, 2023, at 1:00 PM ET in New York. The second is the SVB Securities Global Biopharma Conference on February 16, 2023, at 9:20 AM ET, conducted virtually. Live webcasts will be available on the Company's website, with replays archived post-presentation. Tango is committed to advancing cancer treatment through innovative drug targets and leveraging synthetic lethality principles.

Tango Therapeutics (NASDAQ: TNGX) recently announced significant developments in its clinical pipeline. The U.S. FDA has granted Orphan Drug Designation to TNG908 for treating malignant glioma, enhancing its market exclusivity and providing potential financial incentives. Additionally, the FDA cleared an Investigational New Drug (IND) application for TNG462, a next-generation inhibitor targeting MTAP-deleted cancers, with a clinical trial expected to start in mid-2023. These advancements may broaden the company's strategic options and opportunity to address unmet medical needs in oncology.

Tango Therapeutics (NASDAQ: TNGX) announced the approval of a Clinical Trial Application for TNG908, a PRMT5 inhibitor, by France's ANSM. The company introduced TNG260, targeting STK11-mutant cancers, and TNG348 as a USP1 inhibitor for BRCA1/2-mutant cancers. Aaron Weitzman, M.D., was appointed Chief Medical Officer. Financially, Tango reported Q3 2022 results: collaboration revenue of $6.9 million, a net loss of $29.1 million, and $393.3 million in cash, expected to fund operations into 2025, despite increased R&D and G&A expenses.

Tango Therapeutics (NASDAQ: TNGX), a clinical-stage biotechnology company, announced that its CEO, Barbara Weber, will participate in two investor conferences this November. The first event is the H.C. Wainwright 3rd Annual Precision Oncology Conference on November 14 at 11:00 AM ET, followed by the Jefferies London Healthcare Conference on November 15 at 10:20 AM GMT. Both presentations will be available via live webcast on the company’s website, with replays accessible for 90 days.

Tango Therapeutics (NASDAQ: TNGX) announced the selection of three abstracts for poster presentations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, scheduled from October 26-28, 2022. The posters will cover the characterization and potential of TNG908 and TNG462, both designed to target MTAP-deleted cancers. Notably, TNG908 is highlighted as a brain-penetrant inhibitor, while TNG462 aims to be a best-in-class option. These presentations showcase Tango's focus on precision cancer therapies.

Tango Therapeutics announced the preclinical development of TNG260, a novel CoREST deacetylase inhibitor targeting STK11-mutant cancers. Presenting three abstracts at the 37th Annual Meeting of the Society for Immunotherapy of Cancer from November 8-12, 2022, the company aims to demonstrate how TNG260 potentially overcomes immune evasion associated with STK11 mutations, common in non-small cell lung cancers. Plans include submitting an IND application in H1 2023, highlighting the innovative approach to cancer treatment.

Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company focused on precision cancer medicines, announced that its CEO, Barbara Weber, M.D., will participate in the H.C. Wainwright 24th Annual Global Investment Conference. The presentation will be available on-demand starting September 12, 2022, at 7:00 AM ET. An archived replay will be accessible on the company’s website for approximately 90 days post-event. Tango Therapeutics specializes in discovering novel drug targets, emphasizing precision oncology for cancer treatment.

Tango Therapeutics reported its Q2 2022 financial results, holding $416.4 million in cash. The company is advancing TNG908, an MTA-cooperative PRMT5 inhibitor, in a Phase 1/2 trial for treating MTAP-deleted solid tumors, having received Orphan Drug Designation from the FDA for malignant peripheral nerve sheath tumors. Collaboration revenue decreased to $5.8 million, while research and development expenses rose to $23.7 million. The net loss for Q2 2022 increased to $24.9 million, or $0.28 per share, compared to a loss of $4.5 million, or $0.09 per share, in Q2 2021.